Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Charioteer","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seven Manufacturers Sign Sublicence Agreements with the Medicines Patent Pool to Produce Generic Versions of Shionogi's COVID-19 Oral Antiviral Ensitrelvir to Increase Access in Low- and Middle-Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Charioteer

    Menu

    Charioteer

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Charioteer

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Seven Manufacturers Sign Sublicence Agreements with the Medicines Patent Pool to Produce Generic Versions of Shionogi's COVID-19 Oral Antiviral Ensitrelvir to Increase Acce...

              Details:

              Under the agreement, the 7 selected generic manufacturers will manufacture and supply Xocova (ensitrelvir fumaric acid), an oral antiviral drug for COVID-19 recently approved in Japan, in 117 low and middle income countries.

              Lead Product(s): Ensitrelvir Fumaric Acid

              Therapeutic Area: Infections and Infectious Diseases Product Name: Xocova

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Shionogi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY